Halozyme Therapeutics | HALO - Trade Creditors


Halozyme Therapeutics reported $23.61M in Trade Creditors for its fiscal quarter ending in June of 2026.





Trade Creditors Change Date
Acadia Pharmaceuticals USD 44.57M 32.32M Jun/2026
Agios Pharmaceuticals USD 16.34M 2.6M Jun/2026
Alnylam Pharmaceuticals USD 108.02M 18.61M Jun/2026
Amarin USD 18.8M 29.36M Jun/2026
Amgen USD 2.86B 16.65B Jun/2026
Baxter International USD 1.03B 52M Jun/2026
Cara Therapeutics USD 4.62M 1.4M Mar/2026
Cytokinetics USD 20.51M 4.2M Jun/2026
DBV Technologies USD 39.5M 1.44M Mar/2026
Eli Lilly USD 6.11B 1.08B Jun/2026
Halozyme Therapeutics USD 23.61M 9.51M Jun/2026
Intrexon USD 4.85M 3.12M Jun/2024
Ionis Pharmaceuticals USD 47.7M 21.67M Jun/2026
MannKind USD 11.04M 5.1M Jun/2026
Minerva Neurosciences USD 640K 305K Dec/2025
Nektar Therapeutics USD 10.03M 744K Mar/2026
Pfizer USD 4.58B 75M Jun/2026
Rigel Pharmaceuticals USD 3.85M 3.44M Sep/2025
United Therapeutics USD 497.8M 500K Jun/2026
Vanda Pharmaceuticals USD 39.09M 33.28M Dec/2024